Brain-targeted intranasal delivery of dopamine with borneol and lactoferrin co-modified nanoparticles for treating Parkinson’s disease
| Autor: | Xiucheng Yang, Liuxiang Chu, Xin Yu, Shengnan Tang, Xiuju Yan, Kaoxiang Sun, Rongxia Liu, Zimei Wu, Aiping Wang, Yina Song, Peng Xue |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Parkinson's disease
Dopamine Pharmaceutical Science 02 engineering and technology Pharmacology 030226 pharmacology & pharmacy Rats sprague dawley Borneol Antiparkinson Agents Rats Sprague-Dawley 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Drug Delivery Systems medicine Animals Administration Intranasal Cells Cultured Camphanes biology Lactoferrin business.industry lcsh:RM1-950 Brain borneol Parkinson Disease General Medicine 021001 nanoscience & nanotechnology medicine.disease Rats lactoferrin lcsh:Therapeutics. Pharmacology chemistry biology.protein Parkinson’s disease Nanoparticles Nasal administration nose-to-brain targeted nanoparticles 0210 nano-technology business medicine.drug Research Article |
| Zdroj: | Drug Delivery Drug Delivery, Vol 26, Iss 1, Pp 700-707 (2019) |
| DOI: | 10.6084/m9.figshare.8851424.v1 |
| Popis: | Efficient delivery of brain-targeted drugs is highly important for successful therapy in Parkinson’s disease (PD). This study was designed to formulate borneol and lactoferrin co-modified nanoparticles (Lf-BNPs) encapsulated dopamine as a novel drug delivery system to achieve maximum therapeutic efficacy and reduce side effects for PD. Dopamine Lf-BNPs were prepared using the double emulsion solvent evaporation method and evaluated for physicochemical and pharmaceutical properties. In vitro cytotoxicity studies indicated that treatment with dopamine Lf-BNPs has relatively low cytotoxicity in SH-SY5Y and 16HBE cells. Qualitative and quantitative cellular uptake experiments indicated that Lf modification of NPs increased cellular uptake of SH-SY5Y cells and 16HBE cells, and borneol modification can promote the cellular uptake of 16HBE. In vivo pharmacokinetic studies indicated that AUC0–12 h in the rat brain for dopamine Lf-BNPs was significantly higher (p < .05) than that of dopamine nanoparticles. Intranasal administration of dopamine Lf-BNPs effectively alleviated the 6-hydroxydopamine-induced striatum lesion in rats as indicated by the contralateral rotation behavior test and results for striatal monoamine neurotransmitter content detection. Taken together, intranasal administration of dopamine Lf-BNPs may be an effective drug delivery system for Parkinson’s disease. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|